Paul Araullo
Psychiatric/Mental Health · Compton, CANPI 1053744870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Alkermes, Inc. at 30.8% of the total. Reporting peaked in 2024 at $2,274 and has fallen 79.6% since, to $465 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$733
- AbbVie$666
- Neurocrine Biosciences, Inc.$387
- plus $499 from 6 others
What the payments were for
- Food & beverage$6,65999%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 67 | $2,073 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $1,308 |
| Otsuka America Pharmaceutical, Inc. | 17 | $1,057 |
| Johnson & Johnson | 23 | $733 |
| AbbVie | 57 | $666 |
| Neurocrine Biosciences, Inc. | 7 | $387 |
| Indivior Inc. | 13 | $212 |
| Sunovion Pharmaceuticals Inc. | 11 | $97 |
| Lundbeck LLC | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Sage Therapeutics, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,915
- ARISTADA$979
- CAPLYTA$689
- ABILIFY MAINTENA$350
- REXULTI$348
- ARISTADA INITIO$245
- INGREZZA$239
- INVEGA TRINZA$133
- PERSERIS$125
- ABILIFY ASIMTUFII$119
How this compares
$6,723 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 34 | $212,542 |
| AristadaAripiprazole Lauroxil | 49 | $143,147 |
| LybalviOlanzapine/Samidorphan Malate | 78 | $124,998 |
| Abilify MaintenaAripiprazole | 34 | $93,994 |
| VraylarCariprazine Hcl | 58 | $86,216 |
| RexultiBrexpiprazole | 54 | $85,181 |
| PerserisRisperidone | 31 | $84,353 |
| Invega SustennaPaliperidone Palmitate | 29 | $82,675 |
| CaplytaLumateperone Tosylate | 49 | $81,087 |
| Lurasidone Hcl | 175 | $36,554 |
| VivitrolNaltrexone Microspheres | 15 | $23,968 |
| Clozapine | 212 | $17,302 |
| Chlorpromazine Hcl | 124 | $16,000 |
| Fluvoxamine Maleate | 192 | $8,106 |
| Quetiapine Fumarate | 520 | $8,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $2,073 | $292,112142 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $56 | $212,54234 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,057 | $179,17488 claims |
| AbbVieVraylar | $666 | $86,21658 claims |
| Indivior Inc.Perseris | $212 | $84,35331 claims |
| Johnson & JohnsonInvega Sustenna | $733 | $82,67529 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,308 | $81,08749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Compton
- Dalana GonzalezCompton$12K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.